Why Generics?

Because there is nothing generic about our standards. Our internal teams conduct reviews of all products, start to finish. No matter where in the world they are made.

Why such high standards? Because we truly care about the people who will be helped by the medicines we make. And we believe in earning that trust, from physicians, pharmacists, other healthcare professionals and patients, every day. It’s why we say, “Our Mylan Is Your Mylan.”

Want to know more about generic medicines? See the facts, figures and bioequivalence requirements below.

Percentage of U.S. prescriptions filled with a generic medicine

Number of U.S. prescriptions, brand-name or generic, filled with a Mylan product

Food and Drug Administration: This agency must approve every generic medicine before it can be sold in the U.S.

To gain FDA approval, generic medicines must be proven to be “bioequivalent” to their brand name counterparts. That means generic and brand name medicines are the same in the following ways:

Active ingredient

Maximum amount of medicine in the blood at any given time

Total amount of medicine in the blood from the time it’s taken until the body eliminates it

Strength and dosage

Route of administration—tablet, injection, etc.

Expected safety and efficacy

FDA evaluation of manufacturing facilities

Just because products have the same active ingredient does not mean they are bioequivalent. Once generic bioequivalence is proven, the FDA considers a generic medicine interchangeable with the brand name medicine.

Average amount consumers can save by filling a prescription with a generic rather than a brand name medicine. The price of generic medicines is usually lower, when compared to brand name medicines, since they are not invented from scratch, generally subject to clinical trials or supported by advertising campaigns

$1.46 Trillion! According to IMS Health, generic medications saved the U.S. healthcare system an estimated $1.46 trillion from 2006 to 2015, and $227 billion in 2015 alone.

Main factors behind the growth of the generics industry

Aging population

Desire to reduce healthcare spending

The key to Mylan’s ability to bring new generics to market, especially medicines that are difficult-to-manufacture and difficult-to-formulate. Find out about our therapeutic innovation.

Patients

Physicians

Health Systems Customers

You are leaving Mylan.com

You are now leaving Mylan.com for a Mylan affiliate site, a Mylan product site, a third party site that Mylan may contribute content to but does not have exclusive control over, or a third party site that is solely responsible for its content and may not follow guidelines applicable in certain geographies.